Banque Pictet & Cie 13F: Cuts Moderna (MRNA) Stake by $106M

Banque Pictet & Cie has reduced its holdings in Moderna, Inc. (NasdaqGS: MRNA) by 548,143 shares, as reported in a filing on October 16, 2026. Following this change, the fund now holds approximately 2.15 million shares valued at about $414.3 million. This adjustment reflects a 20.3% decrease in its position.

What Changed in Banque Pictet's Moderna Position

The fund's reduction indicates a shift in its investment strategy, cutting its stake in the biotechnology firm. With this latest move, Banque Pictet has lowered its investment in Moderna, which has been a key player in the healthcare sector, especially known for its messenger RNA medicines.

Other Institutional Activity in Moderna

FMR, LLC boosted its holdings in Moderna by 6,188,477 shares, bringing its total to 51,859,891 shares worth approximately $11.3 billion. Blackrock Inc. also increased its stake by 963,178 shares, totaling 30,599,409 shares valued at about $6.7 billion. Meanwhile, Vanguard Capital Management LLC added 336,227 shares, ending with 23,208,792 shares worth around $5.1 billion. Capital World Investors grew its position by 3,578,829 shares, totaling 22,276,996 shares with a value of about $4.9 billion. Conversely, Baillie Gifford & Co reduced its holdings by 1,778,708 shares, leaving it with 18,206,778 shares worth approximately $3.97 billion.

Moderna, Inc. Stock Down 6.2%

Recently, Moderna's stock traded around $212.26, which is significantly above its 50-day and 200-day moving averages by 43.4% and 181.4%, respectively. However, it remains about 12.4% below its 52-week high of $242.29. The stock is currently trading well above its 52-week low of $22.28, indicating substantial growth over the past year.

Recent Earnings

For the year ending in the most recent quarter, Moderna reported trailing-twelve-month revenue of $2.23 billion, with a year-over-year revenue growth of 2.1%. The company has also faced challenges, as its net margin stands at a loss of 141.4%. The next earnings release is scheduled for November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Insider trading activity has shown some significant movements recently. On August 5, 2026, CEO Stephane J Bancel sold 499,246 shares, valued at about $28.7 million. Other insiders, including Shannon Thyme Klinger and CFO James M Mock, also sold shares earlier in September, demonstrating ongoing insider sales during this period.

Analysts Set New Price Targets

Analysts have had mixed views on Moderna in recent months. On August 28, 2026, Argus Research upgraded the stock to a Buy rating with a target price of $180. In contrast, Rothschild & Co downgraded it to a Sell on September 3 with a target of $81, followed by Citigroup also maintaining a Sell rating with a target of $80 on September 30. The current consensus among analysts gives Moderna a hold rating, with a mean target price of $123.61 based on 18 analyst opinions.

About Moderna, Inc.

Moderna, Inc., headquartered in Cambridge, MA, focuses on the development of messenger RNA medicines. Its innovations in biotechnology have positioned it as a significant player in the healthcare sector, particularly during the pandemic era with its vaccine development efforts. This recent position cut by Banque Pictet reflects changes in investor sentiment toward the biotech industry.

Bottom Line

Investors should keep an eye on Moderna's upcoming earnings report on November 6, 2026, for insights into its recent performance and outlook. The filing from Banque Pictet reflects its holdings as of the reporting quarter and may not represent its current position in the market.